Role of Eosinophils in the Proliferation of Airway Smooth Muscle (ASM) Cells

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Saleh Zaid Al-Muhsen, King Saud University
ClinicalTrials.gov Identifier:
NCT01082952
First received: March 8, 2010
Last updated: October 11, 2011
Last verified: October 2011
  Purpose

Being a key player in Asthma, eosinophils constitute a potential target to interfere with the series of biological events leading to Asthma pathogenesis. In this proposal, the investigators hypothesize that the interaction between eosinophils and airway smooth muscle cells (ASM) cells plays an important role in airway remodeling. Hence the investigators will investigate the role of eosinophils in enhancing ASM cells proliferation resulting in airways remodeling. The investigators will also investigate the mechanism behind this phenomenon. This will then pave the way for medical (drug) interference at one or several sites in order to prevent one of the main potential reasons behind airway remodeling, namely eosinophil-derived ASM proliferation.


Condition
Asthma

Study Type: Observational
Study Design: Observational Model: Case Control
Official Title: Role of Eosinophils in the Proliferation of ASM Cells in Asthma

Resource links provided by NLM:


Further study details as provided by King Saud University:

Primary Outcome Measures:
  • Fold Increase in ASM Proliferation Following Incubation With Eosinophils. [ Time Frame: one day ] [ Designated as safety issue: No ]
    Airway Smooth Muscle (ASM) cell proliferation was measured 24 hrs following their co-culture with eosinophil. This was determined using Ki-67 staining and flowcytometry. The fold increase in ASM proliferation was then determined.


Secondary Outcome Measures:
  • Fold Increase in ASM Cells Proliferation Following Treatment With Cysteinyl Leukotrienes [ Time Frame: one day ] [ Designated as safety issue: No ]
    The effect of Eosinophil release of Cysteinyl Leukotrienes on ASM proliferation was determined using blocking agents. This was determined using Ki-67 staining and flowcytometry.


Enrollment: 12
Study Start Date: January 2010
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Asthmatic patients
Non asthmatic patients

Detailed Description:

Rational and hypothesis Asthma is a chronic inflammatory disorder of the lung airways that is associated with airway remodeling and hyperresponsiveness (AHR). Its is well documented that the smooth muscle mass in asthmatic airways is increased due to hypertrophy and hyperplasia of the ASM cells. Moreover, eosinophils have been proposed in different studies to play a major role in airway remodeling. The association between increased eosinophil numbers and asthma severity has been well documented. Here, we hypothesized that the interaction between eosinophils and ASM cells plays an important role in airway remodeling and that eosinophils modulate the airways through enhancing ASM cell proliferation.

Objectives of the study The aim of this study is to examine the effect of eosinophils on ASM cell proliferation using eosinophils isolated from asthmatic subjects.

Specific aim 1. Effect of co-culture of ASM cells with eosinophils on ASM cell proliferation.

In this specific aim, the effect of eosinophil on ASM cell proliferation will be studied by co-culturing eosinophils isolated from asthmatic and healthy patients with ASM cells in vitro. This will be done using non-stimulated eosinophils or eosinophils activated with Interleukin-5 (IL-5)and Interleukin-3 (IL-3). ASM proliferation will be monitored by determining the levels of the proliferation marker Ki-67 expression in ASM cells.

Specific aim 2. Understanding the mechanism by which eosinophils enhance ASM proliferation.

In this specific aim, we will study the mechanism by which eosinophils enhance the proliferation of ASM cells. To study if this effect of eosinophils is done through direct contact with ASM cells, we will co-culture ASM cells with eosinophils membrane fractions. Moreover, we will examine the effect of cytokines and extracellular matrix (ECM) proteins produced by eosinophils on smooth muscle cells

  Eligibility

Ages Eligible for Study:   14 Years to 35 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

12 patients per group

Criteria

Asthma: Patient Selection (Inclusion Criteria)

  1. Subjects with documented clinical history of asthma for a period of at least 6 months prior to study entry (and a minimum of one clinic follow-up visit since initial diagnosis)
  2. Willing to provide written informed consent and in the judgment of the investigator, individuals who are able to understand the informed consent process.
  3. Subjects with documented clinical history (in preceding 12 months) of airway reversibility of at least 12% based on Forced Expiratory Volume (FEV1), measured pre and post inhalation of a β-2 agonist (2 puffs of albuterol using a measured dose inhaler with spacer) OR
  4. Individuals with strong history of asthma but with waning, or no current symptoms may be included in the study if their asthma was well controlled using an asthma medication. Principal investigator must verify or know the clinical history of an individual before accepting him as an asthmatic individual.
  5. Able to perform Spirometry/FEV1 correctly.

Exclusion Criteria

  1. Age < 5 years
  2. Smoking for 20 years, 1 pack/day or more.
  3. Congestive heart failure.
  4. Chronic Obstructive Pulmonary Disease (COPD).
  5. Chronic lung disease other than asthma and COPD.
  6. Bronchiectasis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01082952

Locations
Saudi Arabia
Prince Naif center for immunological research
Riyadh, Saudi Arabia
Sponsors and Collaborators
King Saud University
Investigators
Study Chair: Saleh Al-Muhsen, MD King Saud University
Principal Investigator: Rabih Halwani, PhD King Saud University
  More Information

Additional Information:
No publications provided

Responsible Party: Saleh Zaid Al-Muhsen, Associate professor, King Saud University
ClinicalTrials.gov Identifier: NCT01082952     History of Changes
Other Study ID Numbers: effect of eosinophil on ASM
Study First Received: March 8, 2010
Results First Received: July 20, 2011
Last Updated: October 11, 2011
Health Authority: Saudi Arabia: Ethics Committee

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on September 18, 2014